Null-point action spectra of the light-growth response were measured for three mutants of Phycomyces blakesleeanus (Burgeff) and compared with the action spectrum of the wild type (WT). The action spectrum for L150, a recently isolated "night-blind" mutant, differs from the WT spectrum. The L150 action spectrum has a depression near 450 nm and small alterations in its long-wavelength cutoff, the same spectral regions where its photogravitropism action spectrum is altered. This indicates that the affected gene product influences both phototropism and the light-growth response. For L85, a "hypertropic" (madH) mutant, the light-growth-response action spectrum is very similar to that of WT even though the photogravitropism action spectrum of L85 has been shown previously to be altered in the near-UV region. The affected gene product in this mutant appears to affect phototropic transduction but not light-growth-response transduction. The action spectrum of C110, a "stiff" (madE) mutant, differs significantly from the WT spectrum near 500 nm, the same spectral region where sporangiophores of madE mutants have been shown to have small alterations in second-derivative absorption spectra. This indicates that the madE gene product may be physically associated with a photoreceptor complex, as predicted by system-analysis studies.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF00197899DOI Listing

Publication Analysis

Top Keywords

action spectrum
28
light-growth response
12
gene product
12
action
9
spectrum
9
action spectra
8
spectra light-growth
8
mutants phycomyces
8
spectrum l150
8
mutant differs
8

Similar Publications

Introduction: Community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) are major global health challenges, with high morbidity and mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness of standard empirical antibiotics, highlighting the need for broader-spectrum agents that target also MDR organisms.

Areas Covered: This review summarizes findings from a PubMed search on the use of ceftobiprole in CAP and HAP.

View Article and Find Full Text PDF

The vagus nerve (VN) is the primary parasympathetic nerve, providing two-way communication between the body and brain through a network of afferent and efferent fibers. Evidence suggests that altered VN signaling is linked to changes in the neuroimmune system, including microglia. Dysfunction of microglia, the resident innate immune cells of the brain, is associated with various neurodevelopmental disorders, including schizophrenia, attention deficit hyperactive disorder (ADHD), autism spectrum disorder (ASD), and epilepsy.

View Article and Find Full Text PDF

The growing incidence of infections caused by antibiotic-resistant strains of pathogens is one of the key challenges of the 21 century. The development of novel technological platforms based on single-cell analysis of antibacterial activity at the whole-microbiome level enables the transition to massive screening of antimicrobial agents with various mechanisms of action. The microbiome of wild animals remains largely underinvestigated.

View Article and Find Full Text PDF

Chemoproteomic Profiling of Clickable Fumarate Probes for Target Identification and Mechanism of Action Studies.

ACS Chem Biol

January 2025

Biogen, Chemical Biology & Proteomics, 225 Binney Street, Cambridge, Massachusetts 02142, United States.

Dimethyl fumarate (DMF) is an established oral therapy for multiple sclerosis worldwide. Although the clinical efficacy of these fumarate esters has been extensively investigated, the mode of action and pharmacokinetics of fumarates have not been fully elucidated due to their broad-spectrum reactivity and complex metabolism in vivo. To better understand the mechanism of action of DMF and its active metabolite, monomethyl fumarate (MMF), we designed and utilized clickable probes to visualize and enrich probe-modified proteins.

View Article and Find Full Text PDF

Tuberculosis (TB), a leading infectious disease caused by the pathogen , poses a significant treatment challenge due to its unique characteristics and resistance to existing drugs. The conventional treatment regimens, which are lengthy and involve multiple drugs, often result in poor patient adherence and subsequent drug resistance, particularly with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. This highlights the urgent need for novel anti-TB therapies and new drug targets.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!